What Did Amgen Lobby US Congress About, During The First Half Of 2021?

As has usually been the case, in the last four years at least -- Amgen's spending falls below Pfizer's. . . but a little ahead of where Merck typically ends up, in any given year. That dynamic continues to hold true -- as a even as a new Administration, and new Democratic majority gets underway. [This dynamic is, in part, a function of relative size, and breadth of products, to be fair, as well.]

While Merck spent about $4.3 million, and Pfizer approached $7 million. . . Amgen spend about $4.7 million, through the front half of 2021 -- on these issues, and pieces of legislation:

. . .Biosimilars reimbursement issues, no specific bill; H.R. 3, Prescription drug pricing issues; FDA issues, no specific bill; Vial size issues; Supply Chain Issues, no specific bill. . .

S. 99 -- The Medicare Drug Price Negotiation Act; Vial size issues, no specific bill; H.R.1319 -- the American Rescue Plan Act of 2021; Changes to Six Protected Classes & Part D Payment Modernization model for CY22. . . Issues related to clinical trial diversity; Issues related to osteoporosis, no specific bill; Issues related to international reference pricing and Most Favored Nation (MFN) model Interim Final Rule; Issues related to the 340B program, no specific bill; Reimbursement for biologics/biosimilars; Issues related to Part D redesign; Medicare Part D access issues for plan year 2020 and 2021, no specific bill; Issues related to patient affordability issues, including copay cards, copay accumulators, National Benefit Payment Parameters; Medicare End Stage Renal Disease Prospective Payment System (ESRD PPS) Proposed Rule (bundled payment for calcimimetics); Patent thickets/product hopping, no specific bill; Mergers/acquisitions, no specific bill. . .

Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico; H.R. 7527, Medical Manufacturing, Economic Development, and Sustainability Act of 2020; Proposed Rule, Guidance Related to the Foreign Tax Credit, Clarification of Foreign-Derived Intangible Income; H.R. 6930, Manufacturing API, Drugs, and Excipients (MADE) in America Act of 2020; Issues related to OECD negotiations on the taxation of global income. . .

Issues related to drug patents and exclusivities, no specific bill; Patent eligibility reform, no specific bill; FTC related issues, no specific bill; Issues related to World Trade Organization IP waiver, no specific bill. . . .

Now you know. . . already missing my baby-girl, and she doesn't fly to Mexico, until. . . tomorrow. . . smile.

नमस्ते